{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T17:15:01Z","timestamp":1763226901038,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010167","name":"Shanghai Shen Kang Hospital Development Center","doi-asserted-by":"publisher","award":["No. SHDC12015129","No. SHDC12017125"],"award-info":[{"award-number":["No. SHDC12015129","No. SHDC12017125"]}],"id":[{"id":"10.13039\/501100010167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010098","name":"Shanghai Association for Science and Technology","doi-asserted-by":"publisher","award":["No. 17411969700","No.18411966500"],"award-info":[{"award-number":["No. 17411969700","No.18411966500"]}],"id":[{"id":"10.13039\/100010098","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Sailing Plan Program","award":["No. 19YF1441200"],"award-info":[{"award-number":["No. 19YF1441200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12072-020-10095-1","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:05:56Z","timestamp":1601366756000},"page":"51-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of peg-interferon\u2013nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB"],"prefix":"10.1007","volume":"15","author":[{"given":"Wei","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiankun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"10095_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ 2019;97:230\u2013238","journal-title":"Bull World Health Organ"},{"issue":"67","key":"10095_CR2","first-page":"370","volume":"2017","author":"EASL","year":"2017","unstructured":"EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"10095_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1\u201398","journal-title":"Hepatol Int"},{"key":"10095_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206\u20131217","journal-title":"N Engl J Med"},{"key":"10095_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet 2018;392:2313\u20132324","journal-title":"Lancet"},{"key":"10095_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/apt.13751","volume":"44","author":"M Vigano","year":"2016","unstructured":"Vigano M, Invernizzi F, Grossi G, et al. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. Aliment Pharmacol Ther 2016;44:653\u2013661","journal-title":"Aliment Pharmacol Ther"},{"key":"10095_CR7","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682\u20132695","journal-title":"N Engl J Med"},{"key":"10095_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777\u2013784","journal-title":"J Hepatol"},{"key":"10095_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/infdis\/jix024","volume":"215","author":"H Chi","year":"2017","unstructured":"Chi H, Hansen BE, Guo S, et al. Pegylated interferon Alfa-2b Add-on treatment in hepatitis b virus envelope antigen-positive chronic hepatitis b patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON). J Infect Dis 2017;215:1085\u20131093","journal-title":"J Infect Dis"},{"key":"10095_CR10","first-page":"25","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide Analog: new switch study. J Clin Transl Hepatol 2018;6:25\u201334","journal-title":"J Clin Transl Hepatol"},{"key":"10095_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","volume":"150","author":"P Marcellin","year":"2016","unstructured":"Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016;150:134\u2013144","journal-title":"Gastroenterology"},{"key":"10095_CR12","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/hep.27586","volume":"61","author":"WP Brouwer","year":"2015","unstructured":"Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology 2015;61:1512\u20131522","journal-title":"Hepatology"},{"key":"10095_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","volume":"59","author":"MR Brunetto","year":"2013","unstructured":"Brunetto MR, Marcellin P, Cherubini B, et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013;59:1153\u20131159","journal-title":"J Hepatol"},{"key":"10095_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","volume":"56","author":"V Rijckborst","year":"2012","unstructured":"Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012;56:1006\u20131011","journal-title":"J Hepatol"},{"key":"10095_CR15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/liv.12725","volume":"35","author":"I Goulis","year":"2015","unstructured":"Goulis I, Karatapanis S, Akriviadis E, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 2015;35:1540\u20131548","journal-title":"Liver Int"},{"key":"10095_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123\u2013129","journal-title":"Lancet"},{"key":"10095_CR17","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1128\/AAC.00249-15","volume":"59","author":"GJ Li","year":"2015","unstructured":"Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother 2015;59:4121\u20134128","journal-title":"Antimicrob Agents Chemother"},{"key":"10095_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/hep.30474","volume":"70","author":"J Liu","year":"2019","unstructured":"Liu J, Li T, Zhang L, et al. The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian patients with chronic hepatitis b: a systematic review. Hepatology 2019;70:1045\u20131055","journal-title":"Hepatology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-020-10095-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T01:21:39Z","timestamp":1632878499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-020-10095-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10095"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10095-1","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Wei Xu, Qiang Li, Chenlu Huang, Qiankun Hu, Xun Qi, Yuxian Huang, Jiming Zhang, Liang Chen declare no competing financial and\/or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All authors read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The funding organizations are public institutions and had no role in the design and conduct of the study; collection, management, and analysis of the data; or preparation, review, and approval of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Sponsor"}},{"value":"The study protocol was approved by the ethics committees of Shanghai Public Health Clinical Center and Huashan Hospital. Written informed consents were obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}